95 related articles for article (PubMed ID: 23545664)
41. Effect of olmesartan on oxidative stress in hemodialysis patients.
Kadowaki D; Anraku M; Tasaki Y; Kitamura K; Wakamatsu S; Tomita K; Gebicki JM; Maruyama T; Otagiri M
Hypertens Res; 2007 May; 30(5):395-402. PubMed ID: 17587751
[TBL] [Abstract][Full Text] [Related]
42. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
[TBL] [Abstract][Full Text] [Related]
43. Effects of Ang II receptor blocker irbesartan on adipose tissue function in mice with metabolic disorders.
Maeda A; Tamura K; Wakui H; Ohsawa M; Azushima K; Uneda K; Kobayashi R; Tsurumi-Ikeya Y; Kanaoka T; Dejima T; Ohki K; Haku S; Yamashita A; Umemura S
Int J Med Sci; 2014; 11(6):646-51. PubMed ID: 24834011
[TBL] [Abstract][Full Text] [Related]
44. Comparative Efficacy of Angiotensin II Type 1 Receptor Blockers Against Ventilator-Induced Diaphragm Dysfunction in Rats.
Hall SE; Ahn B; Smuder AJ; Morton AB; Hinkley JM; Wiggs MP; Sollanek KJ; Hyatt H; Powers SK
Clin Transl Sci; 2021 Mar; 14(2):481-486. PubMed ID: 33222389
[TBL] [Abstract][Full Text] [Related]
45. Diverse effects of long-term treatment with imidapril and irbesartan on cell growth signal, apoptosis and collagen type I expression in the left ventricle of spontaneously hypertensive rats.
Wang JM; Wang Y; Zhu ZS; Zhang MC; Zou Y; Li JJ; Li MJ; Jiang XJ; Li XY
Life Sci; 2004 Jun; 75(4):407-20. PubMed ID: 15147828
[TBL] [Abstract][Full Text] [Related]
46. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients.
Naya M; Tsukamoto T; Morita K; Katoh C; Furumoto T; Fujii S; Tamaki N; Tsutsui H
J Am Coll Cardiol; 2007 Sep; 50(12):1144-9. PubMed ID: 17868805
[TBL] [Abstract][Full Text] [Related]
47. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
Strutz F; Bramlage P; Paar WD
Curr Med Res Opin; 2005 Sep; 21(9):1433-40. PubMed ID: 16197662
[TBL] [Abstract][Full Text] [Related]
48. Significance of pigment epithelium-derived factor levels with angiotensin II type 1 receptor blockers in patients with successful coronary stent implantation.
Sugihara M; Miura S; Takamiya Y; Kiya Y; Arimura T; Iwata A; Kawamura A; Nishikawa H; Yamagishi S; Saku K
J Renin Angiotensin Aldosterone Syst; 2011 Sep; 12(3):320-5. PubMed ID: 21330424
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of two single-pill fixed-dose combinations of angiotensin II receptor blockers/calcium channel blockers in hypertensive patients (EXAMINER study).
Motozato K; Miura S; Shiga Y; Kusumoto T; Adachi S; Inoue T; Fujisawa K; Saku K
Clin Exp Hypertens; 2016; 38(1):45-50. PubMed ID: 26268636
[TBL] [Abstract][Full Text] [Related]
51. Comparison of efficacy of low- (80 mg/day) and high- (160-320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions.
Peters S
Am J Cardiovasc Drugs; 2008; 8(2):83-7. PubMed ID: 18422391
[TBL] [Abstract][Full Text] [Related]
52. Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria.
Rabbani N; Adaikalakoteswari A; Rossing K; Rossing P; Tarnow L; Parving HH; Thornalley PJ
Amino Acids; 2012 May; 42(5):1627-39. PubMed ID: 21384133
[TBL] [Abstract][Full Text] [Related]
53. The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats.
Ersoy R; Celik A; Yilmaz O; Sarioglu S; Sis B; Akan P; Yenicerioglu Y; Ormen M; Camsari T
Perit Dial Int; 2007; 27(4):424-31. PubMed ID: 17602151
[TBL] [Abstract][Full Text] [Related]
54. Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies.
Derosa G; Cicero AF; Carbone A; Querci F; Fogari E; D'Angelo A; Maffioli P
J Am Soc Hypertens; 2013; 7(1):32-9. PubMed ID: 23321403
[TBL] [Abstract][Full Text] [Related]
55. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Croom KF; Curran MP; Goa KL; Perry CM
Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
[TBL] [Abstract][Full Text] [Related]
56. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.
Neutel JM; Franklin SS; Lapuerta P; Bhaumik A; Ptaszynska A
J Hum Hypertens; 2008 Apr; 22(4):266-74. PubMed ID: 17928878
[TBL] [Abstract][Full Text] [Related]
57. [Comparison of the antihypertensive activity of fosinopril and irbesartan].
Angulo E; Robles NR; Grois J; Barquero A; Pérez Miranda M
An Med Interna; 2002 Nov; 19(11):571-5. PubMed ID: 12522893
[TBL] [Abstract][Full Text] [Related]
58. Preferable effects of olmesartan/calcium channel blocker to olmesartan/diuretic on blood pressure variability in very elderly hypertension: COLM study subanalysis.
Rakugi H; Ogihara T; Saruta T; Kawai T; Saito I; Teramukai S; Shimada K; Katayama S; Higaki J; Odawara M; Tanahashi N; Kimura G;
J Hypertens; 2015 Oct; 33(10):2165-72. PubMed ID: 26066644
[TBL] [Abstract][Full Text] [Related]
59. A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review.
Neutel JM
Postgrad Med; 2011 Jul; 123(4):126-34. PubMed ID: 21680997
[TBL] [Abstract][Full Text] [Related]
60. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
